Accustem Sciences Inc. (ACUT) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en New York City, NY, United States. El CEO actual es Wendy E. Blosser.
ACUT tiene fecha de IPO 2022-03-03, 2 empleados a tiempo completo, cotiza en el Other OTC, una capitalización de mercado de $5.79M.
AccuStem Sciences, Inc. operates as a life sciences company focusing on improving outcomes for patients with cancer. It develops StemPrintER technology, a multi-gene prognostic assay to predict the risk of recurrence of Endocrine receptor-positive /HER2- breast cancer; and Spare, a derivative of StemPrintER that combines StemPrintER with two clinical markers. The company is based in New York, New York.
